MedTrace Logo

Alzheimer's Disease THErapy With NEuroaid II

NCT07191028 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2025-09-24

No results posted yet for this study

Summary

ATHENE II is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial designed to evaluate the efficacy and safety of MLC901 in subjects with mild to moderate Alzheimer's disease, as well as its effects on plasma biomarkers compared to placebo.

Conditions

  • Alzheimer's Disease Dementia

Interventions

DRUG

MLC 901

Oral capsule, 2 capsules 3 times a day for 12 months

DRUG

Placebo

Oral capsule, 2 capsules 3 times a day for 12 months

Sponsors & Collaborators

  • National University Hospital, Singapore

    collaborator OTHER

  • Moleac Pte Ltd.

    lead INDUSTRY

Principal Investigators

  • Christopher Li Hsian Chen · National University Hospital, Singapore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2028-06-30
Completion
2028-06-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07191028 on ClinicalTrials.gov